Apolipoprotein E e4 allele affects risk of hyperhomocysteinemia in the elderly

American Journal of Clinical Nutrition

Volumn 84, Issue 6, 2006, Pages 1473-1480

  Ravaglia, Giovanni ^a   Forti, Paola ^a   Maioli, Fabiola ^a   Chiappelli, Martina ^b   Montesi, Fausta ^a   Bianchin, Marisa ^c   Licastro, Federico ^b   Patterson, Christopher ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Ravenna Local Health Unit   (Italy)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Apolipoprotein E; C reactive protein; Elderly; Homocysteine; Lipid metabolism

Indexed keywords

APOLIPOPROTEIN E4; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; VITAMIN B GROUP;

AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; VITAMIN METABOLISM;

EID: 33845500731     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.6.1473     Document Type: Article

References (35)

1. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-37.
2. Eichner JE, Dunn ST, Perveen GP, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-95.
3. Poirer J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005;26:355-61.
4. Manttari M, Manninen V, Palosuo T, Ehnholm C. Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men. Atherosclerosis 2001;156:237-8 (letter).
5. Austin MA, Zhang C, Humphries SE, et al. Heritability of C-reactive protein and association with apolipoprotein E genotypes in Japanese Americans. Ann Intern Med 2004;68:179-88.
6. Judson R, Brain C, Dain B, Windemuth A, Ruano G, Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004;177:345-51.
7. Marz W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 2004;25:2109-19.
8. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004;116(suppl):9S-16S.
9. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-74.
10. Engelhart MJ, Geerling MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia. The Rotterdam Study. Arch Neurol 2004;61:668-72.
11. Schwalbe RA, Coe JE, Nelsestuen GL. Association of rat C-reactive protein and other pentraxins with rat lipoproteins containing apolipoproteins E and A1. Biochemistry 1995;34:10432-9.
12. Rowe IF, Soutar AK, Trayner IM, Thompson GR, Pepys MB. Circulating human C-reactive protein binds very low density lipoproteins. Clin Exp Immunol 1984;58:237-44.
13. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
14. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer Disease. Am J Clin Nutr 2005;82:636-43.
15. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002;288:2015-22.
16. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
17. Herrmann W, Quast S, Ullrich M, Schultze H, Bodis M, Geisel J. Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 1999;144:91-100.
18. McCully KS, Olszewski AJ, Vezeridis MP. Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide. Atherosclerosis 1990;83:197-206.
19. Olszewski AJ, McCully KS. Homocysteine content of lipoproteins in hypercholesterolemia. Atherosclerosis 1991;88:61-8.
20. Ventura P, Panini R, Rosa MC, Gaetti E, Salvioli G. Relevance of different apolipoprotein content in binding of homocysteine to plasma lipoproteins. Nutr Metab Cardiovasc Dis 2003;4:218-26.
21. Ravaglia G, Forti P, Maioli F, et al. Education, occupation, and prevalence of dementia: findings from the Conselice Study. Dement Geriatr Cogn Disord 2002;14:90-100.
22. Ravaglia G, Forti P, Maioli F, et al. Conselice study: a population based survey of brain aging in a municipality of the Emilia Romagna region: (A.U.S.L. Ravenna). Design and methods. Arch Gerontol Geriatr 2001;7:313-24.
23. Valente C, Maione P, Lippi A, et al. (Validation of the Mini-Mental State Examination (MMSE) as a screening instrument for dementia in an Italian population.) G Gerontol 1992;40:161-5 (in Italian).
24. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996;36:378-84.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
26. Ravaglia G, Forti P, Maioli F, et al. Plasma homocysteine and inflammation in elderly patients with cardiovascular disease and dementia. Exp Gerontol 2004;39:443-50.
27. Licastro F, Pedrini S, Ferri C, et al. Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 2000;48:388-91.
28. Ravaglia G, Forti P, Maioli F, et al. Common polymorphisms in methylenetetrahydrofolate reductase (MTHFR): relationships with plasma homocysteine concentrations and cognitive status in elderly Northern Italian subjects. Arch Gerontol Geriatr Suppl 2004;9:339-48.
29. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
30. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
31. Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: Wiley, 1989.
32. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-6.
33. Religa D, Styczynska M, Peplonska B, et al. Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2003;16:64-70.
34. Lin SK, Kao JT, Tsai SM, et al. Association of apolipoprotein E genotypes with serum lipid profiles in a healthy population of Taiwan. Ann Clin Lab Sci 2004;34:443-8.
35. Jacques PK, Kalmbach R, Bagley PJ, et al. The relation between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677 transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002;132:283-8.